Related Experiment Video
Updated: Jul 19, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Neuroinhibitory molecules in Alzheimer's disease
1Cognitive Function Clinic, Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool, L9 7LJ, UK. a.larner@thewaltoncentre.nhs.uk
Journal of Alzheimer'S Disease : JAD
|September 22, 2006
Summary
Aberrant neurite growth is a key sign of Alzheimer's disease. Understanding neuroinhibitory signals is crucial for effective Alzheimer's treatments beyond just boosting neurotrophic activity.
Area of Science:
- Neuroscience
- Neuropathology
- Alzheimer's Disease Research
Background:
- Aberrant neurite growth is a hallmark neuropathological feature in Alzheimer's disease (AD) brains.
- This abnormal growth occurs around amyloid plaques and within the cortical neuropil.
- Disruption of both inhibitory/repulsive and trophic/permissive growth signals may underlie this dystrophic neurite growth.
Purpose of the Study:
- To investigate the contribution of disrupted growth signals to neuropathology in Alzheimer's disease.
- To highlight the limitations of solely targeting neurotrophic activity for therapeutic intervention.
- To begin elucidating the molecular factors responsible for neuroinhibition in the AD brain.
Main Methods:
- Analysis of neuropathological features in Alzheimer's disease brains.
- Investigation of neurotrophic and neuroinhibitory signaling pathways.
- Identification of molecular species mediating neuroinhibitory effects.
Main Results:
- Confirmed aberrant neurite growth as a significant neuropathological signature in Alzheimer's disease.
- Identified disruptions in both inhibitory and trophic signaling as contributors to dystrophic growth.
- Initiated the elucidation of molecular species responsible for neuroinhibitory effects in AD.
Conclusions:
- Therapeutic strategies for Alzheimer's disease should address both neurotrophic and neuroinhibitory mechanisms.
- Solely restoring neurotrophic activity is unlikely to be a successful therapeutic approach for AD.
- Further research into the molecular basis of neuroinhibition is essential for developing comprehensive Alzheimer's treatments.
More Related Videos
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
09:33Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...